Loading…
Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer's Disease
Progressive cognitive decline is the most relevant clinical symptom of Alzheimer's disease (AD). However, the rate of cognitive decline is highly variable between patients. Synaptic deficits are the neuropathological event most correlated with cognitive impairment in AD. Considering the importa...
Saved in:
| Published in: | Frontiers in aging neuroscience 2021-08, Vol.13, p.705989-705989 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c493t-7f61a4169bee527fb91ea43c5f738517af71c7b197dbd677a8ea7c283fccf7c53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c493t-7f61a4169bee527fb91ea43c5f738517af71c7b197dbd677a8ea7c283fccf7c53 |
| container_end_page | 705989 |
| container_issue | |
| container_start_page | 705989 |
| container_title | Frontiers in aging neuroscience |
| container_volume | 13 |
| creator | Dakterzada, Farida David Benítez, Iván Targa, Adriano Lladó, Albert Torres, Gerard Romero, Leila de Gonzalo-Calvo, David Moncusí-Moix, Anna Tort-Merino, Adria Huerto, Raquel Sánchez-de-la-Torre, Manuel Barbé, Ferran Piñol-Ripoll, Gerard |
| description | Progressive cognitive decline is the most relevant clinical symptom of Alzheimer's disease (AD). However, the rate of cognitive decline is highly variable between patients. Synaptic deficits are the neuropathological event most correlated with cognitive impairment in AD. Considering the important role of microRNAs (miRNAs) in regulating synaptic plasticity, our objective was to identify the plasma miRNAs associated with the rate of cognitive decline in patients with mild AD.
We analyzed 754 plasma miRNAs from 19 women diagnosed with mild AD using TaqMan low-density array cards. The patients were grouped based on the rate of decline in the MMSE score after 2 years [ |
| doi_str_mv | 10.3389/fnagi.2021.705989 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e209825d694d4b57bb11fa75b7d60c39</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e209825d694d4b57bb11fa75b7d60c39</doaj_id><sourcerecordid>2564141844</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-7f61a4169bee527fb91ea43c5f738517af71c7b197dbd677a8ea7c283fccf7c53</originalsourceid><addsrcrecordid>eNpdkkFvFCEYhidGY5vaH-DFkHjQy6wwwDBcTDZr1SZrNI2mR8IwH7tsmGGFmU304G-X3alNKxcIPN8DH3mL4iXBC0ob-c4OeuMWFa7IQmAuG_mkOCd1TUtGa_70wfqsuExph_OgFGPePC_OKGNScMzPiz830E0GOrSGA_iEgkW9uykpq0q-R25A37xOvUbLCGiZUjBOj5m-deMW3YaYAK3CZnCjOwC6OgQ_jS4Mpzo9OhjGNKNfnO_Q0v_egushvknog0ugE7wonlntE1zezRfFj49X31efy_XXT9er5bo0TNKxFLYmmpFatgC8EraVBDSjhltBG06EtoIY0RIpurarhdANaGGqhlpjrDCcXhTXs7cLeqf20fU6_lJBO3XaCHGjdByd8aCgwrKpeFdL1rGWi7YlxGrBW9HV2FCZXe9n135qe-hM7jJq_0j6-GRwW7UJB9WwimBKsuDtnSCGnxOkUfUuGfBeDxCmpCouCOaZPd71-j90F6Y45K_KVM0IIw1jmSIzZWJIKYK9fwzB6hgWdQqLOoZFzWHJNa8ednFf8S8a9C_Kq7tB</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564141844</pqid></control><display><type>article</type><title>Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer's Disease</title><source>PubMed (Medline)</source><source>Publicly Available Content (ProQuest)</source><creator>Dakterzada, Farida ; David Benítez, Iván ; Targa, Adriano ; Lladó, Albert ; Torres, Gerard ; Romero, Leila ; de Gonzalo-Calvo, David ; Moncusí-Moix, Anna ; Tort-Merino, Adria ; Huerto, Raquel ; Sánchez-de-la-Torre, Manuel ; Barbé, Ferran ; Piñol-Ripoll, Gerard</creator><creatorcontrib>Dakterzada, Farida ; David Benítez, Iván ; Targa, Adriano ; Lladó, Albert ; Torres, Gerard ; Romero, Leila ; de Gonzalo-Calvo, David ; Moncusí-Moix, Anna ; Tort-Merino, Adria ; Huerto, Raquel ; Sánchez-de-la-Torre, Manuel ; Barbé, Ferran ; Piñol-Ripoll, Gerard</creatorcontrib><description>Progressive cognitive decline is the most relevant clinical symptom of Alzheimer's disease (AD). However, the rate of cognitive decline is highly variable between patients. Synaptic deficits are the neuropathological event most correlated with cognitive impairment in AD. Considering the important role of microRNAs (miRNAs) in regulating synaptic plasticity, our objective was to identify the plasma miRNAs associated with the rate of cognitive decline in patients with mild AD.
We analyzed 754 plasma miRNAs from 19 women diagnosed with mild AD using TaqMan low-density array cards. The patients were grouped based on the rate of decline in the MMSE score after 2 years [<4 points (
= 11) and ≥4 points (
= 8)]. The differentially expressed miRNAs between the two groups were validated in an independent cohort of men and women (
= 53) with mild AD using RT-qPCR.
In the discovery cohort, 17 miRNAs were differentially expressed according to the fold change between patients with faster declines in cognition and those with slower declines. miR-342-5p demonstrated differential expression between the groups and a good correlation with the rate of cognitive decline in the validation cohort (
= -0.28;
= 0.026). This miRNA had a lower expression level in patients who suffered from more severe decline than in those who were cognitively more stable after 2 years (
= 0.049).
Lower levels of miR-342-5p in plasma were associated with faster cognitive decline in patients with mild AD after 2 years of follow-up.</description><identifier>ISSN: 1663-4365</identifier><identifier>EISSN: 1663-4365</identifier><identifier>DOI: 10.3389/fnagi.2021.705989</identifier><identifier>PMID: 34497505</identifier><language>eng</language><publisher>Switzerland: Frontiers Research Foundation</publisher><subject>Alzheimer's disease ; Binding sites ; biomarker ; Biomarkers ; Cognition & reasoning ; Cognitive ability ; cognitive decline ; Hospitals ; Memory ; MicroRNAs ; miR-342-5p ; miRNA ; Neurodegenerative diseases ; Neuropathology ; Neuroscience ; Patients ; Plasma ; Proteins ; Questionnaires ; Synaptic plasticity ; Womens health</subject><ispartof>Frontiers in aging neuroscience, 2021-08, Vol.13, p.705989-705989</ispartof><rights>Copyright © 2021 Dakterzada, David Benítez, Targa, Lladó, Torres, Romero, de Gonzalo-Calvo, Moncusí-Moix, Tort-Merino, Huerto, Sánchez-de-la-Torre, Barbé and Piñol-Ripoll.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 Dakterzada, David Benítez, Targa, Lladó, Torres, Romero, de Gonzalo-Calvo, Moncusí-Moix, Tort-Merino, Huerto, Sánchez-de-la-Torre, Barbé and Piñol-Ripoll. 2021 Dakterzada, David Benítez, Targa, Lladó, Torres, Romero, de Gonzalo-Calvo, Moncusí-Moix, Tort-Merino, Huerto, Sánchez-de-la-Torre, Barbé and Piñol-Ripoll</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-7f61a4169bee527fb91ea43c5f738517af71c7b197dbd677a8ea7c283fccf7c53</citedby><cites>FETCH-LOGICAL-c493t-7f61a4169bee527fb91ea43c5f738517af71c7b197dbd677a8ea7c283fccf7c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2564141844/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2564141844?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25730,27900,27901,36988,36989,44565,53765,53767,75095</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34497505$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dakterzada, Farida</creatorcontrib><creatorcontrib>David Benítez, Iván</creatorcontrib><creatorcontrib>Targa, Adriano</creatorcontrib><creatorcontrib>Lladó, Albert</creatorcontrib><creatorcontrib>Torres, Gerard</creatorcontrib><creatorcontrib>Romero, Leila</creatorcontrib><creatorcontrib>de Gonzalo-Calvo, David</creatorcontrib><creatorcontrib>Moncusí-Moix, Anna</creatorcontrib><creatorcontrib>Tort-Merino, Adria</creatorcontrib><creatorcontrib>Huerto, Raquel</creatorcontrib><creatorcontrib>Sánchez-de-la-Torre, Manuel</creatorcontrib><creatorcontrib>Barbé, Ferran</creatorcontrib><creatorcontrib>Piñol-Ripoll, Gerard</creatorcontrib><title>Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer's Disease</title><title>Frontiers in aging neuroscience</title><addtitle>Front Aging Neurosci</addtitle><description>Progressive cognitive decline is the most relevant clinical symptom of Alzheimer's disease (AD). However, the rate of cognitive decline is highly variable between patients. Synaptic deficits are the neuropathological event most correlated with cognitive impairment in AD. Considering the important role of microRNAs (miRNAs) in regulating synaptic plasticity, our objective was to identify the plasma miRNAs associated with the rate of cognitive decline in patients with mild AD.
We analyzed 754 plasma miRNAs from 19 women diagnosed with mild AD using TaqMan low-density array cards. The patients were grouped based on the rate of decline in the MMSE score after 2 years [<4 points (
= 11) and ≥4 points (
= 8)]. The differentially expressed miRNAs between the two groups were validated in an independent cohort of men and women (
= 53) with mild AD using RT-qPCR.
In the discovery cohort, 17 miRNAs were differentially expressed according to the fold change between patients with faster declines in cognition and those with slower declines. miR-342-5p demonstrated differential expression between the groups and a good correlation with the rate of cognitive decline in the validation cohort (
= -0.28;
= 0.026). This miRNA had a lower expression level in patients who suffered from more severe decline than in those who were cognitively more stable after 2 years (
= 0.049).
Lower levels of miR-342-5p in plasma were associated with faster cognitive decline in patients with mild AD after 2 years of follow-up.</description><subject>Alzheimer's disease</subject><subject>Binding sites</subject><subject>biomarker</subject><subject>Biomarkers</subject><subject>Cognition & reasoning</subject><subject>Cognitive ability</subject><subject>cognitive decline</subject><subject>Hospitals</subject><subject>Memory</subject><subject>MicroRNAs</subject><subject>miR-342-5p</subject><subject>miRNA</subject><subject>Neurodegenerative diseases</subject><subject>Neuropathology</subject><subject>Neuroscience</subject><subject>Patients</subject><subject>Plasma</subject><subject>Proteins</subject><subject>Questionnaires</subject><subject>Synaptic plasticity</subject><subject>Womens health</subject><issn>1663-4365</issn><issn>1663-4365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkkFvFCEYhidGY5vaH-DFkHjQy6wwwDBcTDZr1SZrNI2mR8IwH7tsmGGFmU304G-X3alNKxcIPN8DH3mL4iXBC0ob-c4OeuMWFa7IQmAuG_mkOCd1TUtGa_70wfqsuExph_OgFGPePC_OKGNScMzPiz830E0GOrSGA_iEgkW9uykpq0q-R25A37xOvUbLCGiZUjBOj5m-deMW3YaYAK3CZnCjOwC6OgQ_jS4Mpzo9OhjGNKNfnO_Q0v_egushvknog0ugE7wonlntE1zezRfFj49X31efy_XXT9er5bo0TNKxFLYmmpFatgC8EraVBDSjhltBG06EtoIY0RIpurarhdANaGGqhlpjrDCcXhTXs7cLeqf20fU6_lJBO3XaCHGjdByd8aCgwrKpeFdL1rGWi7YlxGrBW9HV2FCZXe9n135qe-hM7jJq_0j6-GRwW7UJB9WwimBKsuDtnSCGnxOkUfUuGfBeDxCmpCouCOaZPd71-j90F6Y45K_KVM0IIw1jmSIzZWJIKYK9fwzB6hgWdQqLOoZFzWHJNa8ednFf8S8a9C_Kq7tB</recordid><startdate>20210823</startdate><enddate>20210823</enddate><creator>Dakterzada, Farida</creator><creator>David Benítez, Iván</creator><creator>Targa, Adriano</creator><creator>Lladó, Albert</creator><creator>Torres, Gerard</creator><creator>Romero, Leila</creator><creator>de Gonzalo-Calvo, David</creator><creator>Moncusí-Moix, Anna</creator><creator>Tort-Merino, Adria</creator><creator>Huerto, Raquel</creator><creator>Sánchez-de-la-Torre, Manuel</creator><creator>Barbé, Ferran</creator><creator>Piñol-Ripoll, Gerard</creator><general>Frontiers Research Foundation</general><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210823</creationdate><title>Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer's Disease</title><author>Dakterzada, Farida ; David Benítez, Iván ; Targa, Adriano ; Lladó, Albert ; Torres, Gerard ; Romero, Leila ; de Gonzalo-Calvo, David ; Moncusí-Moix, Anna ; Tort-Merino, Adria ; Huerto, Raquel ; Sánchez-de-la-Torre, Manuel ; Barbé, Ferran ; Piñol-Ripoll, Gerard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-7f61a4169bee527fb91ea43c5f738517af71c7b197dbd677a8ea7c283fccf7c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer's disease</topic><topic>Binding sites</topic><topic>biomarker</topic><topic>Biomarkers</topic><topic>Cognition & reasoning</topic><topic>Cognitive ability</topic><topic>cognitive decline</topic><topic>Hospitals</topic><topic>Memory</topic><topic>MicroRNAs</topic><topic>miR-342-5p</topic><topic>miRNA</topic><topic>Neurodegenerative diseases</topic><topic>Neuropathology</topic><topic>Neuroscience</topic><topic>Patients</topic><topic>Plasma</topic><topic>Proteins</topic><topic>Questionnaires</topic><topic>Synaptic plasticity</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dakterzada, Farida</creatorcontrib><creatorcontrib>David Benítez, Iván</creatorcontrib><creatorcontrib>Targa, Adriano</creatorcontrib><creatorcontrib>Lladó, Albert</creatorcontrib><creatorcontrib>Torres, Gerard</creatorcontrib><creatorcontrib>Romero, Leila</creatorcontrib><creatorcontrib>de Gonzalo-Calvo, David</creatorcontrib><creatorcontrib>Moncusí-Moix, Anna</creatorcontrib><creatorcontrib>Tort-Merino, Adria</creatorcontrib><creatorcontrib>Huerto, Raquel</creatorcontrib><creatorcontrib>Sánchez-de-la-Torre, Manuel</creatorcontrib><creatorcontrib>Barbé, Ferran</creatorcontrib><creatorcontrib>Piñol-Ripoll, Gerard</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in aging neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dakterzada, Farida</au><au>David Benítez, Iván</au><au>Targa, Adriano</au><au>Lladó, Albert</au><au>Torres, Gerard</au><au>Romero, Leila</au><au>de Gonzalo-Calvo, David</au><au>Moncusí-Moix, Anna</au><au>Tort-Merino, Adria</au><au>Huerto, Raquel</au><au>Sánchez-de-la-Torre, Manuel</au><au>Barbé, Ferran</au><au>Piñol-Ripoll, Gerard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer's Disease</atitle><jtitle>Frontiers in aging neuroscience</jtitle><addtitle>Front Aging Neurosci</addtitle><date>2021-08-23</date><risdate>2021</risdate><volume>13</volume><spage>705989</spage><epage>705989</epage><pages>705989-705989</pages><issn>1663-4365</issn><eissn>1663-4365</eissn><abstract>Progressive cognitive decline is the most relevant clinical symptom of Alzheimer's disease (AD). However, the rate of cognitive decline is highly variable between patients. Synaptic deficits are the neuropathological event most correlated with cognitive impairment in AD. Considering the important role of microRNAs (miRNAs) in regulating synaptic plasticity, our objective was to identify the plasma miRNAs associated with the rate of cognitive decline in patients with mild AD.
We analyzed 754 plasma miRNAs from 19 women diagnosed with mild AD using TaqMan low-density array cards. The patients were grouped based on the rate of decline in the MMSE score after 2 years [<4 points (
= 11) and ≥4 points (
= 8)]. The differentially expressed miRNAs between the two groups were validated in an independent cohort of men and women (
= 53) with mild AD using RT-qPCR.
In the discovery cohort, 17 miRNAs were differentially expressed according to the fold change between patients with faster declines in cognition and those with slower declines. miR-342-5p demonstrated differential expression between the groups and a good correlation with the rate of cognitive decline in the validation cohort (
= -0.28;
= 0.026). This miRNA had a lower expression level in patients who suffered from more severe decline than in those who were cognitively more stable after 2 years (
= 0.049).
Lower levels of miR-342-5p in plasma were associated with faster cognitive decline in patients with mild AD after 2 years of follow-up.</abstract><cop>Switzerland</cop><pub>Frontiers Research Foundation</pub><pmid>34497505</pmid><doi>10.3389/fnagi.2021.705989</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1663-4365 |
| ispartof | Frontiers in aging neuroscience, 2021-08, Vol.13, p.705989-705989 |
| issn | 1663-4365 1663-4365 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_e209825d694d4b57bb11fa75b7d60c39 |
| source | PubMed (Medline); Publicly Available Content (ProQuest) |
| subjects | Alzheimer's disease Binding sites biomarker Biomarkers Cognition & reasoning Cognitive ability cognitive decline Hospitals Memory MicroRNAs miR-342-5p miRNA Neurodegenerative diseases Neuropathology Neuroscience Patients Plasma Proteins Questionnaires Synaptic plasticity Womens health |
| title | Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer's Disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T17%3A37%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20Levels%20of%20miR-342-5p%20in%20Plasma%20Are%20Associated%20With%20Worse%20Cognitive%20Evolution%20in%20Patients%20With%20Mild%20Alzheimer's%20Disease&rft.jtitle=Frontiers%20in%20aging%20neuroscience&rft.au=Dakterzada,%20Farida&rft.date=2021-08-23&rft.volume=13&rft.spage=705989&rft.epage=705989&rft.pages=705989-705989&rft.issn=1663-4365&rft.eissn=1663-4365&rft_id=info:doi/10.3389/fnagi.2021.705989&rft_dat=%3Cproquest_doaj_%3E2564141844%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c493t-7f61a4169bee527fb91ea43c5f738517af71c7b197dbd677a8ea7c283fccf7c53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2564141844&rft_id=info:pmid/34497505&rfr_iscdi=true |